Valuation: Bioventix PLC

Market Cap 102M 134M 122M 113M 191M 12.47B 200M 1.36B 540M 6.74B 501M 491M 21.35B P/E 2027 *
13.6x
P/E 2028 * -
Enterprise Value 97.26M 127M 116M 108M 182M 11.91B 191M 1.3B 516M 6.43B 478M 468M 20.38B EV / Sales 2027 *
7.5x
EV / Sales 2028 * -
Free-Float
92.29%
Yield 2027 *
7.69%
Yield 2028 * -
1 week-1.02%
Current month-2.50%
1 month+10.17%
3 months+16.42%
6 months+16.42%
Current year+2.36%
1 week 1,900
Extreme 1900
2,000
1 month 1,800
Extreme 1800
2,120
Current year 1,300
Extreme 1300
2,120
1 year 1,300
Extreme 1300
2,165
3 years 1,300
Extreme 1300
5,100
5 years 1,300
Extreme 1300
5,100
10 years 26.51
Extreme 26.51
5,100
Manager TitleAgeSince
Chief Executive Officer 67 22/12/2003
Director of Finance/CFO 67 30/06/2020
Director TitleAgeSince
Director/Board Member 67 24/11/2010
Chairman 66 31/10/2004
Director/Board Member 67 30/06/2020
Date Insider Type Main position Quantity % Market Cap. Importance
28/04/26 Buy

Chief Financial Officer

66 0.0013%
20/04/26 Free

Chief Executive Officer

9,967 0.1908%
20/04/26 Free

Chief Financial Officer

9,967 0.1908%
Change 5-day change 1-year change 3-year change Capi.($)
0.00%-1.02%-7.14%-48.00% 134M
+0.19%-3.96%+54.92%+69.15% 65.42B
-0.14%-3.20%+7.62%+89.74% 58.91B
+0.06%+0.15%+25.94%+87.89% 55.24B
-0.97%-3.91%+12.98%+113.88% 45.66B
-2.83%-7.58%+15.21%+22.34% 41.29B
+3.61%+2.63%+21.96%+46.39% 36.82B
-0.24%-9.59%+126.05%+647.44% 34.48B
+0.03%-0.93%+76.71%+57.74% 32.5B
+20.58%+22.35%-29.03%+482.03% 31.69B
Average +2.03%-0.46%+30.52%+156.86% 40B
Weighted average by Cap. +1.55%-0.98%+33.38%+154.09%

Financials

2027 *2028 *
Net sales 12.96M 16.99M 15.48M 14.33M 24.31M 1.59B 25.45M 173M 68.7M 857M 63.73M 62.4M 2.72B -
Net income 7.51M 9.84M 8.96M 8.3M 14.08M 919M 14.74M 100M 39.79M 497M 36.91M 36.14M 1.57B -
Net Debt -4.62M -6.06M -5.52M -5.11M -8.68M -566M -9.08M -61.81M -24.52M -306M -22.74M -22.27M -969M -
Projected Income Statement - Annual - Bioventix PLC
Logo Bioventix PLC
Bioventix plc is a United Kingdom-based company specializing in the development and commercial supply of high-affinity monoclonal antibodies for applications in clinical diagnostics, such as automated immunoassays used in blood testing. The antibodies created at the Company are generated in sheep and are of particular benefit where the target is present at low concentration and where conventional monoclonal or polyclonal antibodies have failed to produce a suitable reagent. It offers a portfolio of antibodies to customers for both commercial use and research and development purposes, for the diagnosis or monitoring of a range of conditions, including heart disease, cancer, fertility, thyroid function and drug abuse. The Company’s products include sheep monoclonal antibodies (SMAs), Pyrene (HOP-G) ELISA Kits, and Pyrene (HOP-G) Lateral Flow Kits. The Company supplies antibody products and services to the majority of multinational clinical diagnostics companies.
Employees
14
Date Price Change Volume
19/11/26 GBX 1,950.00 0.00% 3,336
18/11/26 GBX 1,950.00 0.00% 8,154
17/11/26 GBX 1,950.00 0.00% 14,380
16/11/26 GBX 1,950.00 -1.02% 36,834
13/11/26 GBX 1,970.00 0.00% 5,503
Trader
-
Investor
-
Global
-
Quality
ESG MSCI
CCC
MarketScreener Ratings - Bioventix PLC
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
1
Last Close Price
19.50GBP
Average target price
39.00GBP
Spread / Average Target
+100.00%

Annual profits - Rate of surprise

Rate of surprise - EPS - Annual - Bioventix PLC
  1. Stock Market
  2. Stocks
  3. BVXP Stock